Latest Orphan drug Stories
DUBLIN, April 1, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/5q5tcr/global_orphan) has announced the addition of the "Concise
Frost & Sullivan: Breakthrough therapies for rare diseases command premium pricing, particularly if no alternatives exist MOUNTAIN VIEW, Calif., March 25, 2014 /PRNewswire/ -- The global orphan
DALLAS, March 22, 2014 /PRNewswire/ -- ReportsnReports.com offers "Global Orphan Drug Market Outlook 2018", "Global Orphan Drugs Market 2014-2018" and "Global Orphan Drug
MarketReportsOnline.com adds "Europe Orphan Drug Market Outlook 2018" report to its research store. Dallas, Texas (PRWEB) March 06, 2014 Purchase
Resolution Promotes Awareness of Rare Diseases Sacramento, CA (PRWEB) February 27, 2014 Today at the state Capitol, Assemblymember Kevin Mullin (D-South
-- If isavuconazole is approved for invasive mucormycosis, QIDP status provides a five-year extension of market exclusivity -- NORTHBROOK, Ill., Feb.
EASTBOURNE, England, February 25, 2014 /PRNewswire/ -- Daval International, the emerging life sciences company focused on the development of novel treatments for serious
LOS ANGELES, Feb. 25, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd.
ALISO VIEJO, Calif., Feb.